These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23495693)

  • 1. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
    McLean BA; Zhabyeyev P; Pituskin E; Paterson I; Haykowsky MJ; Oudit GY
    J Card Fail; 2013 Apr; 19(4):268-82. PubMed ID: 23582093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and potent small-molecule inhibitors of PI3Ks.
    Jeong Y; Kwon D; Hong S
    Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
    Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3 kinase inhibitors in the clinic: an update.
    Kurtz JE; Ray-Coquard I
    Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinases in health and disease.
    Ghigo A; Morello F; Perino A; Hirsch E
    Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K inhibitors as potential therapeutics for autoimmune disease.
    Ball J; Archer S; Ward S
    Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
    Martelli AM; Nyåkern M; Tabellini G; Bortul R; Tazzari PL; Evangelisti C; Cocco L
    Leukemia; 2006 Jun; 20(6):911-28. PubMed ID: 16642045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-Selective PI3K Inhibitors for Various Diseases.
    Bheemanaboina RRY
    Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
    Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y
    Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
    van Beuge MM; Poelstra K; Prakash J
    Expert Opin Drug Deliv; 2012 Jan; 9(1):59-70. PubMed ID: 22111941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Losmapimod: a novel drug against cardiovascular diseases?].
    Dewenter M; Vettel C; El-Armouche A
    Dtsch Med Wochenschr; 2013 Jan; 138(1-2):39-42. PubMed ID: 23250695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
    Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
    J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
    Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
    Shuttleworth SJ; Silva FA; Cecil AR; Tomassi CD; Hill TJ; Raynaud FI; Clarke PA; Workman P
    Curr Med Chem; 2011; 18(18):2686-714. PubMed ID: 21649578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemical biology of phosphoinositide 3-kinases.
    Wymann MP; Schultz C
    Chembiochem; 2012 Sep; 13(14):2022-35. PubMed ID: 22965647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
    Pirozzi F; Ren K; Murabito A; Ghigo A
    Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.